The 5th annual Kier’s Hope 5K Run and Fun Walk — a fundraiser launched by comedian Kier “Junior” Spates to support people with sickle cell disease (SCD) — is set to go this Saturday, June 3, in Dallas. It’s also Kier’s Hope Day in the City of Dallas.
News
People in Ghana with sickle cell disease (SCD) use prevention, monitoring, diagnosis, and treatment to self-manage their condition, but how this is done differs between adults and children, a study finds. People with SCD spoke more about doing things to stay healthy and treat problems that come up, rather…
Hillhurst Biopharmaceuticals announced that the final healthy volunteer has completed the study protocol in a Phase 1 clinical trial testing HBI-002, an oral carbon monoxide treatment being developed for sickle cell disease (SCD). Data are now being analyzed, and Hillhurst expects to announce top-line results before the end…
The Assistance Fund (TAF) has launched a new financial assistance program to cover out-of-pocket medical expenses for people with sickle cell disease (SCD). The program will cover copayments, health insurance premiums, costs related to ground travel needed to get treatment, and genetic testing, for people with SCD who…
Lobe Sciences has partnered with Pentec Health to distribute Altemia, an emulsified formulation of docosahexaenoic acid (DHA), a type of omega-3 fat, for sickle cell disease (SCD) patients in the U.S. and its territories. As part of the agreement, Pentec, which provides clinical nutrition and specialty care…
The investigational oral treatment FTX-6058 effectively raised the level of fetal hemoglobin in a sickle cell disease (SCD) patient to 24.9% in a clinical trial that’s now been placed on hold by regulators. According to the therapy’s developer, Fulcrum Therapeutics, these initial data had been obtained but not…
A Phase 1/2 clinical trial testing Beam Therapeutics’ gene-editing therapy BEAM-101 is continuing to enroll young adults with sickle cell disease (SCD). The study, called BEACON (NCT05456880), is active at five sites, with a waiting list for enrollment, according to Beam, which is sponsoring the trial.
Despite improvements in newborn screening for sickle cell disease (SCD) in Brazil, the mortality rate for children and young adults with the disease remains high, according to a recent study that highlights the burden of the disease and the need for improved healthcare for these patients. Researchers found that the…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to EDIT-301, an experimental cell-based gene-editing therapy given as a one-time infusion for the treatment of sickle cell disease (SCD). The designation is given to spur the development of therapies for diseases affecting fewer than 200,000 people…
A new gene-editing approach called prime editing was able to selectively correct the genetic deficit underlying sickle cell disease (SCD) in stem cells collected from patients, a recent study reported. “We were able to directly fix the sickle cell mutation in human hematopoietic stem cells (HSCs) … which we…
Recent Posts
- Researchers aim to repurpose diabetes drug to treat SCD kidneys
- Alzheimer’s drug memantine may help prevent SCD crises, especially in kids
- Red blood cell breakdown may drive cognitive problems in SCD
- Looking back at the 5 worst sickle cell crises of my life
- Fetal hemoglobin protects against sickle cell lung problems: Study
- Reflecting on a year of choosing myself while living with sickle cell disease
- New year, old goals, because repeating health resolutions works for sickle cell
- Researchers compare gene therapies for sickle cell disease in mice
- Emmaus to sell North American rights to sickle cell treatment Endari
- For sickle cell patients, developing self-advocacy skills starts in childhood